AKTXAkari Therapeutics Plcvs its industry peers
A metric-by-metric comparison of Akari Therapeutics Plc against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AKTXEsta | $1.62T#1 | — | 86904.8x#2 | 4392758.3x#2 | -39.5%#2 | 12.6%#3 | -4695.9%#3 | -93.0%#2 | -155.6%#1 | — | -66.4%#1 | — |
| ABVX | $8.4B#2 | — | — | — | — | — | — | — | — | — | — | — |
| ACIU | $273M#3 | — | — | — | — | — | — | — | — | — | — | — |
| ACUT | — | — | — | — | — | -16.7%#4 | — | — | — | — | — | — |
| ADAG | $176M#4 | — | 5.0x#1 | 23.0x#1 | 7332.8%#1 | 47.3%#2 | -279.5%#1 | -49.8%#1 | — | — | — | — |
| ANL | — | — | — | — | — | 52.5%#1 | -1058.6%#2 | — | — | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. Esta tabla agotó el tiempo durante su construcción, por lo que cubre parte del grupo; los rangos son solo dentro de las filas mostradas y se completará en breve. Table built 2026-09-16.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice